You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDeserpidine
Accession NumberDB01089  (APRD00906)
TypeSmall Molecule
GroupsApproved
DescriptionDeserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior.
Structure
Thumb
Synonyms
(3beta,16beta,17alpha,18beta,20alpha)-17-Methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
11-demethoxyreserpine
11-desmethoxyreserpine
Canescine
Deserpidina
Deserpidine
Deserpidinum
Harmonyl
Raunormine
Recanescine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HarmonylAbbott
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9016E3VB47
CAS number131-01-1
WeightAverage: 578.6527
Monoisotopic: 578.262816202
Chemical FormulaC32H38N2O8
InChI KeyCVBMAZKKCSYWQR-WCGOZPBSSA-N
InChI
InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8-tetraene-19-carboxylate
SMILES
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications Not Available
PharmacodynamicsDeserpidine, an alkaloid of Rauwolfia canescens, is used as an antihypertensive. Rauwolfia alkaloids work by controlling nerve impulses along certain nerve pathways. As a result, they act on the heart and blood vessels to lower blood pressure.
Mechanism of actionDeserpidine's mechanism of action is through inhibition of the ATP/Mg2+ pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.
TargetKindPharmacological actionActionsOrganismUniProt ID
Synaptic vesicular amine transporterProteinyes
inhibitor
HumanQ05940 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include dizziness or drowsiness (severe), flushing of skin, pinpoint pupils of eyes and slowed pulse.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Deserpidine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Deserpidine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Deserpidine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Deserpidine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Deserpidine.Approved, Withdrawn
AmbrisentanDeserpidine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineDeserpidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Deserpidine.Approved
AtenololAtenolol may increase the hypotensive activities of Deserpidine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Deserpidine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Deserpidine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Deserpidine.Withdrawn
BepridilBepridil may increase the hypotensive activities of Deserpidine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Deserpidine.Approved
BethanidineBethanidine may increase the hypotensive activities of Deserpidine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Deserpidine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Deserpidine.Approved
BosentanBosentan may increase the hypotensive activities of Deserpidine.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Deserpidine.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Deserpidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Deserpidine.Approved
BupranololBupranolol may increase the hypotensive activities of Deserpidine.Approved
CandesartanCandesartan may increase the hypotensive activities of Deserpidine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Deserpidine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Deserpidine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Deserpidine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Deserpidine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Deserpidine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Deserpidine.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Deserpidine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Deserpidine.Approved
CilazaprilCilazapril may increase the hypotensive activities of Deserpidine.Approved
ClonidineClonidine may increase the hypotensive activities of Deserpidine.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Deserpidine.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Deserpidine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Deserpidine.Approved
DihydralazineDeserpidine may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Deserpidine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Deserpidine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Deserpidine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Deserpidine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Deserpidine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Deserpidine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Deserpidine.Approved
EprosartanEprosartan may increase the hypotensive activities of Deserpidine.Approved
FelodipineFelodipine may increase the hypotensive activities of Deserpidine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Deserpidine.Approved
FosinoprilFosinopril may increase the hypotensive activities of Deserpidine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Deserpidine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Deserpidine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Deserpidine.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Deserpidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Deserpidine.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Deserpidine.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Deserpidine.Approved
HydralazineHydralazine may increase the hypotensive activities of Deserpidine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Deserpidine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Deserpidine.Approved
IloprostIloprost may increase the hypotensive activities of Deserpidine.Approved, Investigational
ImidaprilDeserpidine may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Deserpidine.Approved
IndenololIndenolol may increase the hypotensive activities of Deserpidine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Deserpidine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Deserpidine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Deserpidine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Deserpidine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Deserpidine.Approved
IsradipineIsradipine may increase the hypotensive activities of Deserpidine.Approved
KetanserinDeserpidine may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the hypotensive activities of Deserpidine.Approved
LacidipineLacidipine may increase the hypotensive activities of Deserpidine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Deserpidine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Deserpidine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Deserpidine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Deserpidine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Deserpidine.Approved
MacitentanDeserpidine may increase the hypotensive activities of Macitentan.Approved
ManidipineManidipine may increase the hypotensive activities of Deserpidine.Approved
MebanazineMebanazine may increase the hypotensive activities of Deserpidine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Deserpidine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Deserpidine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Deserpidine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Deserpidine.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Deserpidine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Deserpidine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Deserpidine.Approved, Investigational
MetyrosineDeserpidine may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Deserpidine.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Deserpidine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Deserpidine.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Deserpidine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Deserpidine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Deserpidine.Approved
MoxonidineMoxonidine may increase the hypotensive activities of Deserpidine.Approved
NadololNadolol may increase the hypotensive activities of Deserpidine.Approved
NaftopidilDeserpidine may increase the hypotensive activities of Naftopidil.Investigational
NebivololNebivolol may increase the hypotensive activities of Deserpidine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Deserpidine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Deserpidine.Approved
NicorandilNicorandil may increase the hypotensive activities of Deserpidine.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Deserpidine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Deserpidine.Approved
NimodipineNimodipine may increase the hypotensive activities of Deserpidine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Deserpidine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Deserpidine.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Deserpidine.Approved
ObinutuzumabDeserpidine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Deserpidine.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Deserpidine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Deserpidine.Investigational
OxprenololOxprenolol may increase the hypotensive activities of Deserpidine.Approved
PargylinePargyline may increase the hypotensive activities of Deserpidine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Deserpidine.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Deserpidine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Deserpidine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Deserpidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Deserpidine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Deserpidine.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Deserpidine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Deserpidine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Deserpidine.Approved
PinacidilPinacidil may increase the hypotensive activities of Deserpidine.Withdrawn
PindololPindolol may increase the hypotensive activities of Deserpidine.Approved
PirlindolePirlindole may increase the hypotensive activities of Deserpidine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Deserpidine.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Deserpidine.Approved
PrazosinPrazosin may increase the hypotensive activities of Deserpidine.Approved
PropranololPropranolol may increase the hypotensive activities of Deserpidine.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Deserpidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Deserpidine.Approved
RamiprilRamipril may increase the hypotensive activities of Deserpidine.Approved
RasagilineRasagiline may increase the hypotensive activities of Deserpidine.Approved
RemikirenRemikiren may increase the hypotensive activities of Deserpidine.Approved
RescinnamineDeserpidine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Deserpidine.Approved
RilmenidineDeserpidine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatDeserpidine may increase the hypotensive activities of Riociguat.Approved
RituximabDeserpidine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Deserpidine.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Deserpidine.Experimental
SelegilineSelegiline may increase the hypotensive activities of Deserpidine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Deserpidine.Approved
SildenafilSildenafil may increase the antihypertensive activities of Deserpidine.Approved, Investigational
SitaxentanDeserpidine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Deserpidine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Deserpidine.Approved, Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Deserpidine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Deserpidine.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Deserpidine.Approved, Investigational
TiboloneTibolone may increase the hypotensive activities of Deserpidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Deserpidine.Withdrawn
TimololTimolol may increase the hypotensive activities of Deserpidine.Approved
TolazolineTolazoline may increase the hypotensive activities of Deserpidine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Deserpidine.Approved
TorasemideTorasemide may increase the hypotensive activities of Deserpidine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Deserpidine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Deserpidine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Deserpidine.Approved
TravoprostTravoprost may increase the hypotensive activities of Deserpidine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Deserpidine.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Deserpidine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Deserpidine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Deserpidine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Deserpidine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Deserpidine.Approved
ValsartanValsartan may increase the hypotensive activities of Deserpidine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Deserpidine.Approved
VinpocetineDeserpidine may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the hypotensive activities of Deserpidine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Deserpidine.Approved, Vet Approved
Food InteractionsNot Available
References
Synthesis Reference

Gabriele Fontana, Ezio Bombardelli, Cristian Samori, Eleonora Baldelli, Andrea Guerrini, Arturo Battaglia, Bruno Danieli, “Process for the Semisynthesis of Deserpidine.” U.S. Patent US20080242864, issued October 02, 2008.

US20080242864
General ReferencesNot Available
External Links
ATC CodesC02AA05C02LA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9353
Blood Brain Barrier+0.9496
Caco-2 permeable+0.6582
P-glycoprotein substrateSubstrate0.8178
P-glycoprotein inhibitor IInhibitor0.8302
P-glycoprotein inhibitor IINon-inhibitor0.8096
Renal organic cation transporterInhibitor0.5326
CYP450 2C9 substrateNon-substrate0.894
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.7198
CYP450 1A2 substrateInhibitor0.8392
CYP450 2C9 inhibitorNon-inhibitor0.8701
CYP450 2D6 inhibitorNon-inhibitor0.9064
CYP450 2C19 inhibitorNon-inhibitor0.8954
CYP450 3A4 inhibitorNon-inhibitor0.8353
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7081
Ames testNon AMES toxic0.9234
CarcinogenicityNon-carcinogens0.9484
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0921 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7952
hERG inhibition (predictor II)Non-inhibitor0.6277
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228-232Ulshafer, P.R.; US. Patent 2,982,769; May 2, 1961; assigned to Ciba Pharmaceutical.
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0111 mg/mLALOGPS
logP4.25ALOGPS
logP3.69ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)16.37ChemAxon
pKa (Strongest Basic)7.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area108.55 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity154.96 m3·mol-1ChemAxon
Polarizability62.59 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassYohimbine alkaloids
Sub ClassNot Available
Direct ParentYohimbine alkaloids
Alternative Parents
Substituents
  • Yohimbine
  • Corynanthean skeleton
  • Yohimbine alkaloid
  • Pyridoindole
  • Beta-carboline
  • Gallic acid or derivatives
  • P-methoxybenzoic acid or derivatives
  • M-methoxybenzoic acid or derivatives
  • Benzoate ester
  • Indole or derivatives
  • Indole
  • Benzylether
  • Benzoic acid or derivatives
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Methyl ester
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Sievert MK, Hajipour AR, Ruoho AE: Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels. Anal Biochem. 2007 Aug 1;367(1):68-78. Epub 2007 May 3. [PubMed:17559790 ]
  2. Naudon L, Leroux-Nicollet I, Raisman-Vozari R, Botton D, Costentin J: Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse. 1995 Sep;21(1):29-36. [PubMed:8525459 ]
  3. Erickson JD, Eiden LE, Hoffman BJ: Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7. [PubMed:1438304 ]
  4. Mandela P, Chandley M, Xu YY, Zhu MY, Ordway GA: Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochem Int. 2010 May-Jun;56(6-7):760-7. doi: 10.1016/j.neuint.2010.02.011. Epub 2010 Feb 20. [PubMed:20176067 ]
  5. Fulton SC, Healy MD: Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines. Fed Proc. 1976 Dec;35(14):2558-62. [PubMed:11134 ]
  6. Loeffler LJ, Schran HF: Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay. J Pharm Sci. 1979 Nov;68(11):1433-5. [PubMed:574544 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23